Clinical Trial Update: A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC) [Phase 4]

View source ↗

Summary

A Phase 4 trial (TOPIC) examined the impact of Pulmozyme withdrawal on exercise tolerance in cystic fibrosis patients with severe lung disease. The study was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Pulmozyme (dornase alfa)

Snippet

Sponsor: Genentech, Inc. | Conditions: Cystic Fibrosis | Phase 4 | Status: TERMINATED | Results posted: 2010-11-16